Global Blood Therapeutics, Inc. (Gbt) Announced That The Medicines And Healthcare Products Regulatory Agency (Mhra) Has Granted Great Britain Marketing Authorization For Oxbryta (Voxelotor) For The Treatment Of Haemolytic Anaemia Due To Sickle Cell Disease (Scd) In Adult And Paediatric Patients 12 Years Of Age And Older As Monotherapy Or In Combination With Hydroxycarbamide (Hydroxyurea). Voxelotor, An Oral Treatment Taken Once Daily, Is The First Medicine Authorized In Great Britain That Directly Inhibits Sickle Haemoglobin (Hbs) Polymerization, The Molecular Basis Of Sickling And Destruction Of Red Blood Cells In Scd.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!